biostudies-literatureSiddiqa AChina Postdoctoral Science Foundation Fund841https://www.ebi.ac.uk/biostudies/studies/S-EPMC9319355biostudies-literatureUnknown15(7)<i>N</i>-(4-bromophenyl)furan-2-carboxamide (<b>3</b>) was synthesized by the reaction furan-2-carbonyl chloride (<b>1</b>) and 4-bromoaniline (<b>2</b>) in the presence of Et₃N in excellent yields of 94%. The carboxamide (<b>3</b>) was arylated by employing triphenylphosphine palladium as a catalyst and K₃PO₄ as a base to afford <i>N</i>-(4-bromophenyl)furan-2-carboxamide analogues (<b>5a-i</b>) in moderate to good yields (43-83%). Furthermore, we investigated the in vitro anti-bacterial activities of the respective compounds against clinically isolated drug-resistant bacteria <i>A. baumannii</i>, <i>K. pneumoniae</i>, <i>E. cloacae</i> and <i>S. aureus</i>. The molecule (<b>3</b>) was found to be the most effective activity against these bacteria, particuPharmaceuticals (Basel, Switzerland)Synthesis of Functionalized <i>N</i>-(4-Bromophenyl)furan-2-carboxamides via Suzuki-Miyaura Cross-Coupling: Anti-Bacterial Activities against Clinically Isolated Drug Resistant <i>A. baumannii</i>, <i>K. pneumoniae</i>, <i>E. cloacae</i> and MRSA and Its Validation via a Computational Approach.PMC9319355ZC304021910Mahmood SImran MAshraf GAZubair MBilal MAhmad GRasool NQamar MUKhalid ASiddiqa AfalseSynthesis of Functionalized <i>N</i>-(4-Bromophenyl)furan-2-carboxamides via Suzuki-Miyaura Cross-Coupling: Anti-Bacterial Activities against Clinically Isolated Drug Resistant <i>A. baumannii</i>, <i>K. pneumoniae</i>, <i>E. cloacae</i> and MRSA and Its Validation via a Computational Approach.<i>N</i>-(4-bromophenyl)furan-2-carboxamide (<b>3</b>) was synthesized by the reaction furan-2-carbonyl chloride (<b>1</b>) and 4-bromoaniline (<b>2</b>) in the presence of Et₃N in excellent yields of 94%. The carboxamide (<b>3</b>) was arylated by employing triphenylphosphine palladium as a catalyst and K₃PO₄ as a base to afford <i>N</i>-(4-bromophenyl)furan-2-carboxamide analogues (<b>5a-i</b>) in moderate to good yields (43-83%). Furthermore, we investigated the in vitro anti-bacterial activities of the respective compounds against clinically isolated drug-resistant bacteria <i>A. baumannii</i>, <i>K. pneumoniae</i>, <i>E. cloacae</i> and <i>S. aureus</i>. The molecule (<b>3</b>) was found to be the most effective activity against these bacteria, particu2022-01-01T00:00:00Z2022 Jul2026-04-08T12:11:55.18Z2022-08-06T14:59:30.051ZS-EPMC93193553589014010.3390/ph15070841